Latest Breaking News On - Allergan united states inc - Page 1 : comparemela.com

United States - Patent - In Re Cellect: What's The Issue And What To Expect

The Supreme Court is about to receive a Petition for Certiorari in a case that impacts how long a patent protects new inventions, we expect. Specifically, the case addresses the Patent Term.

New yorkUnited statesPatent officeSupreme courtAllergan united states incPatent office trialFood drug administrationAurobindo pharma ltdSee allergan united states incFoley hoagUs patent officeWhat congressPatent term adjustmentObviousness type double patentingFederal circuitPatent trial

In Re Cellect: What's The Issue and What to Expect | Foley Hoag LLP

What Congress has guaranteed, the courts have taken away - The Supreme Court is about to receive a Petition for Certiorari in a case that impacts how long a patent.

United statesPatent officeSee allergan united states incFood drug administrationPatent office trialAllergan united states incAurobindo pharma ltdSupreme courtUs patent officeWhat congressPatent term adjustmentObviousness type double patentingFederal circuitPatent trialAppeal boardType double patenting

The Case Law on Obviousness-Type Double Patenting: How We Got Here and a Proposal for Change (Part II)

The Case Law on Obviousness-Type Double Patenting: How We Got Here and a Proposal for Change (Part II)
ipwatchdog.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ipwatchdog.com Daily Mail and Mail on Sunday newspapers.

Breckenridge pharmNovartis pharmsAllergan united states incNatco pharma ltdUs courtGilead sciences incAcadia pharamceuticals incEzra venturesAurobindo pharma ltdFederal circuitGilead sciencesPharma ltdUruguay round agreements actJudge raderOut exceptionsPatent term extension

Safe Harbor Protection: Acadia Pharms., Inc. v. Aurobindo Pharma Ltd. - Patent

In Acadia Pharms., Inc. v. Aurobindo Pharma Ltd., No. 20-985-GBW (D. Del. Dec. 2023), the district court granted Acadia's motion for summary judgment of no invalidity.

Allergan courtBarr labs incAurobindo pharma ltdDistrict courtAcadia pharms incAllergan united states incAcadia pharmsPharma ltdAnswering briefBoehringer ingelheimAllergan united statesSafe harbor protection acadia pharms Ncv aurobindo pharma ltd Life sciencesLife sciencesIotechnology amp nanotechnology

In Wake Of In Re Cellect, District Court Interprets Safe Harbor Statute And Finds Patent Not Invalid For Obviousness-Type Double Patenting - Patent

The requirement that the "divisional application is filed before the issuance of the patent…" is inapplicable when the challenged patent issues from the original application.

United statesDistrict courtKey holdingsGilead scis incNatco pharma ltdTrademark officeAllergan united states incFederal circuitGilead scisPharma ltdIn wake of re cellectIstrict court interprets safe harbor statute and finds patent not invalid for obviousness type double patentingIntellectual property